Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Estradiol in Metastatic TNBC
NCT01083641Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2010
- Primary completion
- Jun 2013
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estradiol in triple negative breast cancer (TNBC), sponsored by University of Wisconsin–Madison. Primary endpoint: Tumor Objective Response Rates up to 4 years. Started Jan 2010; status: terminated.
02
Drugs
estradiol
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01083641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083641.